Table 2: Comparison of epidemiological, clinical and treatment data in psoriatic arthritis patients with and without anxiety and correlation of anxiety with quality of life, depression, age, disease duration and activity indexes.
|
COMPARISON STUDIES |
||||
|
|
With anxiety N = 34 (62.9%) |
Without anxiety N = 20 (37.0%) |
P |
|
|
Females/Males |
18/16 |
9/11 |
0.57 |
|
|
Tobacco exposure |
20 (58.8%) |
7 (35%) |
0.09 |
|
|
Arthritis subset |
|
|
0.67 |
|
|
Polyarthritis |
11 (32.2%) |
3 (15%) |
|
|
|
Oligoarthritis |
18 (52.9%) |
12 (80%) |
|
|
|
Axial |
16 (47.0%) |
8 (40%) |
|
|
|
Distal interphalangeal |
3 (6.7%) |
2 (10%) |
|
|
|
Treatment |
||||
|
DMARDs (Methotrexate + leflunomide) |
22 (64.7%) |
12 (60%) |
0.72 |
|
|
Anti-TNF-alpha |
13 (38.2%) |
5 (25%) |
0.38
|
|
|
CORRELATION STUDIES OF BECK ANXIETY INVENTORY RESULTS: |
||||
|
|
Rho |
95% Confidence interval |
P |
|
|
Age |
0.05 |
-022 to +0.32 |
0.70 |
|
|
Arthritis duration |
-0.23 |
-0.48 to +0.04 |
0.09 |
|
|
Psoriasis duration |
-0.02 |
-0.30 to +0.25 |
0.85 |
|
|
PASI |
0.42 |
+0.16 to +0.62 |
0.001 |
|
|
ASDAS -ESR |
0.39 |
+0.13 to 0.60 |
0.003 |
|
|
ASDAS-CRP |
0.25 |
-0.02 to 0.49 |
0.06 |
|
|
CRP |
-0.04 |
-0.31 to +0.24 |
0.77 |
|
|
ESR |
0.22 |
-0.55 to +0.47 |
0.09 |
|
|
CES-D |
0.80 |
+0.68 to +0.88 |
< 0.0001 |
|
|
SF-12 (physical domain) |
-0.60 |
-0.75 to -0.39 |
< 0.0001 |
|
|
SF-12 (mental domain) |
-0.70 |
-0.82 to -0.53 |
< 0.0001 |
|
DMARDs: Disease Modifying Rheumatic Drugs; PASI: Psoriasis Area Severity Index; ASDAS: Ankylosing Spondylitis Disease Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; CES-D: Center for Epidemiological Studies Depression scale; SF-12: Short Form health survey with 12 questions